Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 High-dose epoetin alfa as induction treatment for severe anemia in multiple myeloma patients.

Literature DB >> 19609645

High-dose epoetin alfa as induction treatment for severe anemia in multiple myeloma patients.

Tommaso Caravita^1,2, Agostina Siniscalchi³, Marco Montanaro⁴, Pasquale Niscola³, Roberto Stasi⁵, Sergio Amadori³, Paolo de Fabritiis³.

Abstract

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2009 PMID： 19609645 DOI： 10.1007/s12185-009-0378-2

Source DB: PubMed Journal: Int J Hematol ISSN： 0925-5710 Impact factor: 2.490

× No keyword cloud information.

11 in total

1. Epoetin alfa 40000 U once weekly and intravenous iron supply in solid tumor patients: early increase of hemoglobin level during chemotherapy.

Authors: M Lalle; G Pistillucci; M Antimi; M D'Aprile
Journal: J Exp Clin Cancer Res Date: 2005-06

Review 2. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update.

Authors: J Douglas Rizzo; Mark R Somerfield; Karen L Hagerty; Jerome Seidenfeld; Julia Bohlius; Charles L Bennett; David F Cella; Benjamin Djulbegovic; Matthew J Goode; Ann A Jakubowski; Mark U Rarick; David H Regan; Alan E Lichtin
Journal: Blood Date: 2007-10-22 Impact factor: 22.113

3. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

Authors: T J Littlewood; E Bajetta; J W Nortier; E Vercammen; B Rapoport
Journal: J Clin Oncol Date: 2001-06-01 Impact factor: 44.544

Review 4. Predictors of response to erythropoiesis-stimulating agents (ESA) in cancer patients: the role of baseline serum epoetin level.

Authors: Jaime Sanz Ortiz
Journal: Clin Transl Oncol Date: 2008-08 Impact factor: 3.405

Review 5. The use of erythropoiesis-stimulating agents in patients with non-myeloid hematological malignancies: a systematic review.

Authors: Nadine Shehata; Irwin Walker; Ralph Meyer; Adam E Haynes; Kevin Imrie
Journal: Ann Hematol Date: 2008-07-16 Impact factor: 3.673

6. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

Authors: G D Demetri; M Kris; J Wade; L Degos; D Cella
Journal: J Clin Oncol Date: 1998-10 Impact factor: 44.544

Review 7. The role of iron supplementation during epoietin treatment for cancer-related anemia.

Authors: M Hedenus; G Birgegård
Journal: Med Oncol Date: 2008-05-13 Impact factor: 3.064

Review 8. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations.

Authors: Heinz Ludwig; Kanti Rai; Joan Blade; Franco Dammacco; Laurent Degos; Loretta Itri; Robert Kyle; Vicenzo Liso; Timothy James Littlewood; Franco Mandelli; Giovanna Meloni; Stefano Molica; Anders Osterborg; Gerassimos A Pangalis; Jesus San Miguel; Barbara Schmitt; Dimitrios Voliotis
Journal: Hematol J Date: 2002

High-dose epoetin alfa as induction treatment for severe anemia in multiple myeloma patients.

1. Epoetin alfa 40000 U once weekly and intravenous iron supply in solid tumor patients: early increase of hemoglobin level during chemotherapy.

Review 2. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update.

3. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

Review 4. Predictors of response to erythropoiesis-stimulating agents (ESA) in cancer patients: the role of baseline serum epoetin level.

Review 5. The use of erythropoiesis-stimulating agents in patients with non-myeloid hematological malignancies: a systematic review.

6. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

Review 7. The role of iron supplementation during epoietin treatment for cancer-related anemia.

Review 8. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations.

Review 9. Cancer-related anemia and recombinant human erythropoietin--an updated overview.

10. Managing anemia in lymphoma and multiple myeloma.

Review 1. Erythropoietin or darbepoetin for patients with cancer.

2. Hepcidin and GDF15 in anemia of multiple myeloma.